Antisoma Starts Phase II Trial of AS1404 in Ovarian Cancer
07 juin 2005 02h09 HE
|
Antisoma plc
LONDON, June 7, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) announces that it has started a phase II trial of its vascular disrupting agent AS1404 in recurrent ovarian cancer. This...
Antisoma and Heraeus Sign Agreement for Manufacture of AS1410
02 juin 2005 02h11 HE
|
Antisoma plc
LONDON and HANAU, Germany, June 2, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) announces that it has signed an agreement with German specialist manufacturer Heraeus to provide...
Antisoma to Present at Needham & Company Fourth Annual Biotechnology Conference on May 26 2005
23 mai 2005 09h21 HE
|
Antisoma plc
LONDON, May 23, 2005 (PRIMEZONE) -- Antisoma plc (LSE:ASM) today announces that its Chief Executive Officer, Glyn Edwards, will be presenting at the Needham & Company Fourth Annual Biotechnology...
Promising Phase I Data for Antisoma's AS1411 Revealed at ASCO
16 mai 2005 02h09 HE
|
Antisoma plc
LONDON and ORLANDO, Fla., May 16, 2005 (PRIMEZONE) -- American Society of Clinical Oncology Meeting -- Cancer drug developer Antisoma (LSE:ASM) announces the presentation at ASCO of promising phase I...
ASCO Presentation Underlines Leading Position of Antisoma's AS1404
16 mai 2005 02h06 HE
|
Antisoma plc
LONDON, May 16, 2005 (PRIMEZONE) -- American Society of Clinical Oncology Meeting, Orlando, Fla., -- Cancer drug developer Antisoma (LSE:ASM) announces the presentation at ASCO of positive phase I...
Antisoma Reviews Portfolio: Drops AS1405 to Accelerate AS1411
05 mai 2005 02h07 HE
|
Antisoma plc
LONDON, May 5, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma (LSE:ASM) today announces that it plans to expand and accelerate trials of its aptamer drug AS1411, following an internal review of...
Antisoma Presents Promising AS1411 Data at TIDES Meeting
04 mai 2005 02h08 HE
|
Antisoma plc
LONDON and BOSTON, May 4, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) yesterday presented preclinical data showing the strong anti-cancer potential of its aptamer drug AS1411...
Antisoma to present at Rodman and Renshaw Healthcare Conference on May 4
29 avr. 2005 05h27 HE
|
Antisoma plc
LONDON, April 29, 2005 (PRIMEZONE) -- Cancer drug developer Antisoma plc (LSE:ASM) today announces that its Chief Executive Officer, Glyn Edwards, will be presenting at the Rodman & Renshaw...
Antisoma: IND Granted for Phase II Study
19 avr. 2005 02h08 HE
|
Antisoma plc
-- U.S. IND granted for phase II study in prostate cancer
-- AACR presentations on Antisoma's AS1404: promising prostate and ovarian cancer data support trial plans
LONDON, April 19, 2005...
Winning features of Antisoma's AS1410 unveiled at AACR
18 avr. 2005 02h09 HE
|
Antisoma plc
ANAHEIM, Calif. and LONDON April 18, 2005 (PRIMEZONE) -- American Association of Cancer Research Meeting in Anaheim, California -- Cancer drug developer Antisoma plc (LSE:ASM) today presents the...